Retinal inner layer thinning detected by OCT offers a promising biomarker for monitoring multiple sclerosis progression.

New study shows oral microbiome imbalance and reduced salivary hypotaurine may contribute to neuroinflammation in relapsing-remitting MS.

Scientists at UCSF have uncovered evidence that multiple sclerosis silently damages the brain years before diagnosis. By ...

Researchers have traced the earliest stages of multiple sclerosis (MS), showing that the immune system begins attacking the brain up to seven years before diagnosis.

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...

Selma Blair’s lifelong health struggles were signs of multiple sclerosis that doctors wouldn't acknowledge until she was in ...

Researchers have identified two compounds, K102 and K110, that could repair the nerve damage from multiple sclerosis. These drugs help regenerate the protective myelin sheath and balance immune ...

Purpose Multiple sclerosis (MS) is a chronic neurological condition that affects approximately 150 000 people in the UK and presents a significant healthcare burden, including the high costs of ...

Scientists have identified an unusual type of brain cell that may play a vital role in progressive multiple sclerosis (MS), likely contributing to the persistent inflammation characteristic of the ...

Fox News national correspondent Madison Scarpino reports on an explosion at the Accurate Energetic Systems explosives manufacturing plant in Tennessee that destroyed the building and resulted in ...

Researchers have identified two compounds capable of repairing the protective myelin sheath damaged by multiple sclerosis, a major advance toward reversing nerve injury rather than just slowing it.

VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug ...